Kidd Mark, Modlin Irvin M, Mane Shrikant M, Camp Robert L, Shapiro Michael D
Department of Surgery, Yale University School of Medicine, New Haven, CT 06520-8062, USA.
Ann Surg. 2006 Feb;243(2):273-80. doi: 10.1097/01.sla.0000197734.28551.0f.
Message and protein expression of CgA was examined to evaluate the sensitivity of a PCR-based approach in the detection of covert neuroendocrine (NE) tissue.
Immunohistochemical (IHC) measurement of chromogranin A (CgA) discriminates gastrointestinal (GI) carcinoids from epithelial tumors. IHC is, however, an insensitive technique to identify micrometastases or delineate subpopulations of NE cells.
CgA gene expression was examined by Q-RT PCR in GI carcinoids (small intestinal and metastases, n=17, gastric, n=5), appendiceal tumors (n=10), and adenocarcinomas (gastric, n=5, colorectal, n=6). CgA protein expression levels were quantitatively analyzed following IHC by automated quantitative analysis (AQUA) in 2 tissue microarrays (GI carcinoid and GI adenocarcinoma).
CgA gene was overexpressed (P<0.001) in GI carcinoids compared with GI adenocarcinomas and normal mucosa. Elevated levels (P<0.00001) were also identified in carcinoid liver and lymph node (LN) metastases. CgA levels were higher (approximately 2-4-fold) in NE appendiceal carcinoids than in adenocarcinoids, but in GI adenocarcinomas were identical to normal mucosa. Histologically normal lymph nodes expressed detectable CgA message in 30% of cases. CgA protein levels were highest in primary GI carcinoids and in liver metastases and significantly elevated (P<0.005) compared with nonmetastatic lesions. Expression in liver and LN metastases was significantly elevated (P<0.000001) compared with normal. Analysis of mRNA by Q-RT PCR was >200-fold more sensitive than by IHC.
Overexpression of CgA mRNA and protein in GI carcinoids can identify metastatic cells; thus, PCR for CgA can be used to identify micrometastases not evident by light microscopy or IHC as well as define tumors of ambivalent morphologic phenotype. The use of this sensitive strategy to assess NETs and apparently normal LNs and liver may be of future utility in defining therapeutic strategy.
检测嗜铬粒蛋白A(CgA)的信息和蛋白表达,以评估基于聚合酶链反应(PCR)的方法在检测隐匿性神经内分泌(NE)组织中的敏感性。
嗜铬粒蛋白A(CgA)的免疫组织化学(IHC)检测可区分胃肠道(GI)类癌与上皮性肿瘤。然而,IHC对于识别微转移灶或描绘NE细胞亚群是一种不敏感的技术。
通过实时定量逆转录PCR(Q-RT PCR)检测GI类癌(小肠及转移灶,n = 17;胃,n = 5)、阑尾肿瘤(n = 10)及腺癌(胃,n = 5;结直肠,n = 6)中CgA基因的表达。在2个组织芯片(GI类癌和GI腺癌)中,通过自动定量分析(AQUA)对IHC后的CgA蛋白表达水平进行定量分析。
与GI腺癌和正常黏膜相比,GI类癌中CgA基因过表达(P < 0.001)。在类癌肝转移和淋巴结(LN)转移中也发现CgA水平升高(P < 0.00001)。NE阑尾类癌中的CgA水平高于腺类癌(约2 - 4倍),但在GI腺癌中与正常黏膜相同。组织学上正常的淋巴结在30%的病例中表达可检测到的CgA信息。CgA蛋白水平在原发性GI类癌和肝转移中最高,与非转移病变相比显著升高(P < 0.005)。与正常组织相比,肝和LN转移中的表达显著升高(P < 0.000001)。通过Q-RT PCR分析mRNA的敏感性比IHC高200倍以上。
GI类癌中CgA mRNA和蛋白的过表达可识别转移细胞;因此,CgA的PCR可用于识别光学显微镜或IHC未发现的微转移灶,并确定形态学表型不明确的肿瘤。使用这种敏感策略评估神经内分泌肿瘤(NETs)以及看似正常的LN和肝脏,可能对未来确定治疗策略具有重要意义。